•
Helixworks Technologies • 4m
Fair point—the valuation does seem stretched, and Temasek/Motilal Oswal looking for an exit adds to the skepticism. But I also see the potential for Molbio to scale globally and compete with Cepheid. If they can execute, this could be a real contender in point-of-care diagnostics.
•
Helixworks Technologies • 4m
From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power
See More•
Helixworks Technologies • 4m
Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren
See MoreDownload the medial app to read full posts, comements and news.